Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

NCT06868017 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT06868017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06868017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
February 19, 2027
Enrollment
208 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive breast cancer